Efficacy Models: Acute Ventricular Arrhythmias
What are the appropriate therapeutic endpoints toward which therapy for acute ventricular arrhythmias should be directed? Is suppression of spontaneous ventricular ectopy although it is asymptomatic sufficient to assure protection against the recurrence of symptomatic ventricular tachyarrhythmias? Is reproduction of life- threatening arrhythmia by electrophysiologic testing reauired to evaluate the efficacy of therapeutic regimens for patients with ventricular tachyarrhythmias? These Questions must be answered as we evolve the correct approach to the treatment of patients with life-threatening ventricular tachyarrhythmias. In the consideration of which drugs are effective there is an implicit assumption made that we know how to evaluate what is appropriate and correct therapy; however, this issue is probably more in question than the efficacy of specific drugs and devices. Not only must we consider the capabilities of the various techniques to identify the correct regimen but we must also consider the technical expertise and cost involved.